KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $4.0 million.

  • Adaptive Biotechnologies' Depreciation and Depletion fell 4.47% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year decrease of 11.14%. This contributed to the annual value of $17.6 million for FY2024, which is 14.28% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Depreciation and Depletion stood at $4.0 million for Q3 2025, which was down 2.50% from $4.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Depreciation and Depletion's 5-year high stood at $5.3 million during Q3 2023, with a 5-year trough of $2.3 million in Q1 2021.
  • In the last 3 years, Adaptive Biotechnologies' Depreciation and Depletion had a median value of $4.6 million in 2024 and averaged $4.6 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 128.44% in 2021, then fell by 21.97% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Depreciation and Depletion (Quarterly) stood at $4.5 million in 2021, then climbed by 8.76% to $4.9 million in 2022, then grew by 2.18% to $5.0 million in 2023, then dropped by 18.05% to $4.1 million in 2024, then dropped by 4.47% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.1 million for Q2 2025, and $4.3 million during Q1 2025.